Dermatologist · UCLH · United Kingdom (GB) · Immunology
Data minimisation
Cadence target for Tier 1: 4 per year (assumption)
1 of 2 expected engagements
All engagements including drafts, newest first
| Date | Type | Format | MSL | Product | Topics | Insights | Flags | Status | |
|---|---|---|---|---|---|---|---|---|---|
| 10 Aug 2026 | Advisory board | In person | Rachel Adeyemi | Aurelin | JAK1/TYK2 selectivityLong-term safety monitoring+1 | 0 | — | Reviewed | ENG-0230 |
| 11 Mar 2026 | Congress meeting | Phone | Rachel Adeyemi | Aurelin | Adolescent population | 0 | — | Reviewed | ENG-0232 |
| 05 Mar 2026 | Scientific exchange | In person | Rachel Adeyemi | Aurelin | JAK1/TYK2 selectivityPhase IIb efficacy | 0 | — | Reviewed | ENG-0234 |
| 25 Jan 2026 | Scientific exchange | Virtual | Rachel Adeyemi | Aurelin | Adolescent population | 1 | MI request | Reviewed | ENG-0229 |
10 Aug 2026
JAK1/TYK2 selectivity, Long-term safety monitoring, Phase IIb efficacy
11 Mar 2026
Adolescent population
05 Mar 2026
JAK1/TYK2 selectivity, Phase IIb efficacy
25 Jan 2026
Adolescent population
UCLH
Oncology pharmacist
Pathologist
Pathologist
Renal pathologist
Academic nephrologist
Renal pathologist
Dermatologist